| | Baseline | Acute effect | Sustained effect |
|---|
| | 8.00 a.m. | 12.00 a.m. | 8.00 a.m. | 12.00 a.m. | 8.00 a.m. |
|---|
FMDbase (mm) | 3.8 [3.3-4.2] | 3.8 [3.4-4.2] | 3.7 [3.3-4.2] | 3.6 [3.3-4.1] | 3.6 [3.4-4.3] |
FMDmax(mm) | 3.9 [3.5-4.3] | 4.0 [3.6-4.3] | 3.8 [3.5-4.3] | 3.9 [3.5-4.3] | 3.8 [3.6-4.4] |
FMDmax (%) | 4.8 [2.4-6.5] | 5.3 [2.2-7.5] | 5.0 [2.4-7.9] | 4.9 [2.7-9.8] | 6.1 [4.3-8.2] |
NMDbase (mm) | 3.6 [3.2-4.2] | 4.1 [3.4-4.2] | 3.8 [3.1-4.4] | 4.1 [3.3-4.4] | 3.7 [3.3-4.2] |
NMDmax (mm) | 4.4 [4.1-4.8] | 4.4 [4.2-4.9] | 4.4 [3.9-5.0] | 4.4 [4.1-5.1] | 4.4 [4.1-4.9] |
NMDmax (%) | 19.1 [13.2-25.7] | 17.0 [12.5-23.7] | 16.7 [13.0-24.6] | 17.3 [9.8-23.7] | 21.1 [13.5-29.6] |
- Values are presented as median values (Q1 – Q3). FMDbase: diameter of brachial artery before hyperaemic stimulus; FMDmax : maximum dilation of brachial artery after hyperaemic stimulus, shown in mm as maximum percentage change in brachial artery diameter compared with FMDbase; NMDbase: diameter of brachial artery before application of 0.4 mg nitroglycerine; NMDmax: maximum dilation of brachial artery after application of 0.4 mg nitroglycerine, shown in mm and as maximum percentage change in brachial artery diameter compared with FMDbase.. Baseline: FMD at 08.00 and 12.00 at study visit 1 (without ivabradine); Acute effect: FMD before and 4 hours after first intake of 7,5 mg ivabradine; Sustained effect: FMD after 4 weeks of ivabradine intake twice daily (10 to 15 mg).
